Protagonist Therapeutics, Inc (PTGX)

Import this data to Google Sheets with:

=jivedata("PTGX","financials")

Full statements spill as a table. For one cell: =jivedata("PTGX","Revenue") or =jivedata("PTGX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Protagonist Therapeutics, Inc

PTGX • CIK 0001377121

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Including Assessed Tax	$60,000	$434,433	$46,016	$74,063
Operating Income (Loss)	$-93,652	$252,843	$-158,127	$58,342
Investment Income, Interest	$14,898	$26,315	$28,789	$26,115
Other Nonoperating Income (Expense)	$-201	$250	$27	$-119
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-78,955	$279,408	$-129,311	$84,338
Income Tax Expense (Benefit)	$0	$4,220	$838	$1,429
Net Income (Loss) Attributable to Parent	$-78,955	$275,188	$-130,149	$82,909
Weighted Average Number of Shares Outstanding, Basic	56,763,559	61,566,989	63,573,048	65,848,516
Weighted Average Number of Shares Outstanding, Diluted	56,763,559	65,077,722	63,573,048	71,153,084
Research and Development Expense	$120,161	$138,128	$159,290	$175,161
General and Administrative Expense	$33,491	$43,462	$44,853	$48,489
Operating Expenses	$153,652	$181,590	$204,143	$223,650

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$186,727	$97,249	$128,390	$420,078
Marketable Securities, Current	$154,890	$321,664	$438,974	$362,498
Marketable Securities, Noncurrent	—	$140,252	$78,638	$66,875
Receivables, Long-term Contracts or Programs	—	—	$121	$13,416
Property, Plant and Equipment, Net	$1,195	$3,190	$3,860	$3,456
Prepaid Expense and Other Assets, Current	$3,960	$7,728	$10,089	$7,790
Restricted Cash, Noncurrent	$225	$225	$287	$287
Assets, Current	$355,577	$591,641	$577,574	$807,148
Operating Lease, Right-of-Use Asset	$954	$9,417	$7,829	$6,946
Assets	$357,951	$744,725	$668,188	$885,544
Operating Lease, Liability, Noncurrent	$1,141	$10,356	$8,040	$6,820
Liabilities	$21,274	$69,430	$53,481	$44,001
Accounts Payable, Current	$772	$1,615	$5,339	$3,459
Other Accounts Payable and Accrued Liabilities	$19,358	$23,693	$28,269	$21,667
Deferred Income, Current	—	$18,891	$9,550	$9,659
Accrued Income Taxes, Current	—	$2,689	$2,689	$1,889
Operating Lease, Liability, Current	$1,141	$510	$2,283	$2,396
Liabilities, Current	$21,274	$47,398	$45,441	$37,181
Deferred Revenue, Noncurrent	—	$11,676	$11,676	$2,788
Common Stock, Value, Issued	$1	$1	$1	$1
Additional Paid in Capital, Common Stock	$952,491	$1,015,898	$1,084,736	$1,146,409
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-105	$-82	$641	$-828
Retained Earnings (Accumulated Deficit)	$-615,710	$-340,522	$-470,671	$-304,039
Stockholders' Equity Attributable to Parent	$336,677	$675,295	$614,707	$841,543
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	90,000,000	180,000,000	180,000,000	180,000,000
Common Stock, Shares, Issued	57,708,613	61,035,139	62,577,897	64,672,032

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-78,955	$275,188	$-130,149	$82,909
Net Cash Provided by (Used in) Operating Activities	$-70,236	$184,152	$57,671	$131,197
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$60,983	$-89,478	$31,203	$251,532
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$186,952	$97,474	$128,677	$182,799
Share-based Payment Arrangement, Noncash Expense	$29,293	$37,554	$45,974	$49,816
Payments to Acquire Debt Securities, Available-for-sale	$191,045	$621,702	$546,585	$469,035
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	$152,396	$323,574	$491,840	$544,988
Depreciation, Depletion and Amortization	$977	$826	$1,280	$1,541
Proceeds from Sale and Maturity of Marketable Securities	—	—	$7,003	$3,384
Accretion (Amortization) of Discounts and Premiums, Investments	$4,569	$8,875	$7,223	$5,091
Payments to Acquire Property, Plant, and Equipment	$609	$1,355	$1,590	$615
Other Operating Activities, Cash Flow Statement	$194	$194	$-8	$-17
Net Cash Provided by (Used in) Investing Activities	$-39,258	$-299,483	$-49,332	$78,722
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	$4,774	$26,453	$23,343	$41,613
Increase (Decrease) in Prepaid Expense and Other Assets	$-1,753	$3,768	$2,360	$-1,984
Increase (Decrease) in Accounts Payable, Trade	$-2,868	$842	$3,723	$214
Proceeds from Issuance of Common Stock	$107,798	$107,798	$107,798	$107,798
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	$-5,597	$4,289	$4,576	$6,352
Proceeds from Debt, Net of Issuance Costs	$24,302	$24,302	$24,302	$24,302
Increase (Decrease) in Accounts Payable, Related Parties	$-66	$-3	$-3	$-3
Increase (Decrease) in Contract with Customer, Liability	$-1,601	$30,567	$-21,017	$-10,404
Proceeds from Warrant Exercises	$559	$559	$559	$559
Increase (Decrease) in Income Taxes Payable	—	$2,689	$-2,689	$-2,689
Net Cash Provided by (Used in) Financing Activities	$170,477	$25,853	$22,864	$41,613
Operating Lease, Payments	$2,743	$2,226	$903	$903
Income Taxes Paid, Net	—	$1,530	$3,694	$3,694
Capital Expenditures Incurred but Not yet Paid	$61	$46	$46	—
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$1,373	$10,511	$10,511	$10,511

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("PTGX","financials")

Full statements spill as a table. For one cell: =jivedata("PTGX","Revenue") or =jivedata("PTGX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.